Outcomes following TAVR in patients with cardiogenic shock: A systematic review and meta-analysis
Recommended Citation
Jabri A, Ayyad M, Albandak M, Al-Abdouh A, Madanat L, Khalefa BB, Alhuneafat L, Ayyad A, Lemor A, Mhanna M, Al Jebaje Z, Fadel R, Gonzalez PE, O'Neill B, Bagur R, Hanson ID, Abbas AE, Frisoli T, Lee J, Wang DD, Aggarwal V, Alaswad K, O'Neill WW, Aronow HD, AlQarqaz M, and Villablanca P. Outcomes following TAVR in patients with cardiogenic shock: A systematic review and meta-analysis. Cardiovasc Revasc Med 2024.
Document Type
Article
Publication Date
8-17-2024
Publication Title
Cardiovasc Revasc Med
Abstract
BACKGROUND: While transcatheter aortic valve replacement (TAVR) has broadened treatment options for critically ill patients, outcomes among those with concomitant cardiogenic shock (CS) are not well-explored.
METHODS: We conducted a comprehensive search of major databases for studies comparing outcomes following TAVR in patients with and without CS since inception up to October 31, 2023. Our meta-analysis included five non-randomized observational. Dichotomous outcomes were assessed using the Mantel-Haenszel method (risk ratio, 95 % CI), and continuous outcomes were evaluated using mean difference and 95 % CI with the inverse variance method. Statistical heterogeneity was determined using the inconsistency test (I(2)).
RESULTS: Among 26,283 patients across five studies, 30-day mortality was higher in the CS group (7267 patients; 27.6 %) compared to those without CS (OR 3.41, 95 % CI [2.01, 5.76], p < 0.01), as well as 30-day major vascular complications (OR 1.72, 95 % CI [1.54, 1.92], p < 0.01). At 1-year follow-up, there was no statistically significant difference in mortality rates between the compared groups (OR 2.68, 95 % CI [0.53, 13.46], p = 0.12). No significant between-group differences were observed in the likelihood of 30-day aortic valve reintervention (OR 3.20, 95 % CI [0.63, 16.22], p = 0.09) or post-TAVR aortic insufficiency (OR 0.91, 95 % CI [0.33, 2.51], p = 0.73). Furthermore, 30-day stroke, pacemaker implantation, and in-hospital major bleeding were comparable between both cohorts.
CONCLUSION: Among patients undergoing TAVR, short-term mortality is higher but one-year outcomes are similar when comparing those with, to those without, CS. Future studies should examine whether TAVR outcomes are improved when the procedure is delayed to optimize CS and when delay is not possible, whether particular management strategies lead to more favorable periprocedural outcomes.
PubMed ID
39209579
ePublication
ePub ahead of print
